Literature DB >> 1473001

Corticotropin-releasing factor induces a place aversion independent of its neuroendocrine role.

M Cador1, S H Ahmed, G F Koob, M Le Moal, L Stinus.   

Abstract

The purpose of the present experiment was to test the hypothesis that corticotropin-releasing factor (CRF), a polypeptide of 41 amino acids, when administered either intracerebroventricularly (i.c.v.) or subcutaneously (s.c.), has aversive properties in the conditioned place-preference paradigm. Five doses of CRF (0, 0.005, 0.05, 0.5, 5 micrograms) were tested. i.c.v. CRF induced a specific dose-dependent reduction of the amount of time spent in the environment previously paired with the administration of CRF. Furthermore, this CRF-induced place aversion was prevented by pretreatment with alpha-helical-CRF(9-41), a specific CRF antagonist, administered i.c.v. In order to test whether the aversive effects induced by i.c.v. CRF could result from the stimulation of the HPA axis accompanying i.c.v. CRF injection, the reinforcing properties of s.c. CRF were studied using the same dose range. Only the higher s.c. dose was effective in producing a place aversion suggesting that the aversive effects of CRF could not be due solely to the stimulation of the pituitary-adrenocortical system, measured by plasmatic levels of adrenocorticotropic hormone (ACTH) and corticosterone, because the lower doses consistently activate the pituitary-adrenocortical system without producing any behavioral changes. Altogether, these data indicate that the non-neurosecretory CRF neurons may mediate the aversive state occurring during stress.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1473001     DOI: 10.1016/0006-8993(92)91487-y

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  24 in total

Review 1.  Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.

Authors:  George F Koob
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

2.  Effects of stress modulation on morphine-induced conditioned place preferences and plasma corticosterone levels in Fischer, Lewis, and Sprague-Dawley rat strains.

Authors:  Ivana Grakalic; Charles W Schindler; Michael H Baumann; Kenner C Rice; Anthony L Riley
Journal:  Psychopharmacology (Berl)       Date:  2006-10-03       Impact factor: 4.530

3.  Corticotropin-releasing factor in ventromedial prefrontal cortex mediates avoidance of a traumatic stress-paired context.

Authors:  Allyson L Schreiber; Yi-Ling Lu; Brittni B Baynes; Heather N Richardson; Nicholas W Gilpin
Journal:  Neuropharmacology       Date:  2016-05-24       Impact factor: 5.250

4.  Anxiogenic and aversive effects of corticotropin-releasing factor (CRF) in the bed nucleus of the stria terminalis in the rat: role of CRF receptor subtypes.

Authors:  Lacey L Sahuque; Erika F Kullberg; Andrew J Mcgeehan; Jennifer R Kinder; Megan P Hicks; Mary G Blanton; Patricia H Janak; M Foster Olive
Journal:  Psychopharmacology (Berl)       Date:  2006-03-28       Impact factor: 4.530

5.  Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2.

Authors:  J Radulovic; A Rühmann; T Liepold; J Spiess
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

6.  Corticotropin-releasing factor-1 receptor activation mediates nicotine withdrawal-induced deficit in brain reward function and stress-induced relapse.

Authors:  Adrie W Bruijnzeel; Melissa Prado; Shani Isaac
Journal:  Biol Psychiatry       Date:  2009-02-12       Impact factor: 13.382

Review 7.  Corticotropin-Releasing Factor (CRF) Neurocircuitry and Neuropharmacology in Alcohol Drinking.

Authors:  Allyson L Schreiber; Nicholas W Gilpin
Journal:  Handb Exp Pharmacol       Date:  2018

Review 8.  The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors.

Authors:  M R Bruchas; B B Land; C Chavkin
Journal:  Brain Res       Date:  2009-08-28       Impact factor: 3.252

Review 9.  Drug withdrawal conceptualized as a stressor.

Authors:  Elena H Chartoff; William A Carlezon
Journal:  Behav Pharmacol       Date:  2014-09       Impact factor: 2.293

10.  CRF1-R activation of the dynorphin/kappa opioid system in the mouse basolateral amygdala mediates anxiety-like behavior.

Authors:  Michael R Bruchas; Benjamin B Land; Julia C Lemos; Charles Chavkin
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.